TELOMIR PHARMACEUTICALS INC (TELO) Stock Earnings & Estimates
USA - NASDAQ:TELO - US87975F1049 - Common Stock
1.415 USD
+0.08 (+6.39%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | |||||
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -138.1K | -854.1K -518.46% | -3.942M -361.55% | -11.642M -195.33% | N/A 38.60% | N/A -6.36% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A 29.63% | N/A 26.32% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.07 | -0.07 27.14% | -0.07 -2.00% | -0.07 58.00% | -0.08 -14.29% | -0.06 14.29% |
| Revenue Q2Q % growth | 510K | 1.02M | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -2.257M 62.42% | -2.284M 21.40% | N/A | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.17 | -0.08 | -0.09 | -108.33% |
| Q1 2025 Q2Q % growth | -0.07 | -0.10 | 0.03 | 31.37% |
| Q4 2024 Q2Q % growth | -0.10 | -0.05 | -0.05 | -92.16% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 12.5% | 30% | -22.58% | 5% |
| Revenue | N/A | N/A | N/A | N/A |